Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 1;16:51. doi: 10.1186/s12885-016-2074-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Legendre et al. 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Deferasirox inhibits proliferation linked with increased cytotoxicity and apoptosis in glioblastoma cells under normoxic conditions. Number of nuclei of U251 (a) and U87 (d) glioblastoma cells cultivated at 21 % of oxygen in non-treated condition (CONT) or 3 days after treatment with 5 μM of ferric ammonium citrate (FAC), or with 10 μM of deferasirox and 5 μM of FAC (DFX + FAC) or with 10 μM of deferasirox (DFX) in non-irradiated condition (0 Gy) or following irradiation with 16 Gy (16 Gy). The number of nuclei are expressed as mean ± standard deviation (S.D.) (n = 3). Measure of lactate dehydrogenase (LDH) release into cell culture medium of U251 (b) and U87 (e) glioblastoma cells cultivated at 21 % of oxygen in untreated condition (CONT) or 3 days after treatment with 5 μM of ferric ammonium citrate (FAC), or with 10 μM of deferasirox and 5 μM of FAC (DFX + FAC) or with 10 μM of deferasirox (DFX) in non-irradiated condition (0 Gy) or following irradiation with 16 Gy (16 Gy). Cytotoxicity is expressed as mean percentage ± standard deviation (S.D.) (n = 3) of the total amount of LDH released from cells and relative to glioblastoma cells treated with 0.1 % Triton X-100, given the arbitrary percentage of 100. DEVD-AMC caspase 3 activity in U251 (c) and U87 (f) glioblastoma cells cultivated at 21 % of oxygen in untreated condition (CONT) or 3 days after treatment with 5 μM of ferric ammonium citrate (FAC), or with 10 μM of deferasirox and 5 μM of FAC (DFX + FAC) or with 10 μM of deferasirox (DFX) in non-irradiated condition (0 Gy) or following irradiation with 16 Gy (16 Gy). Caspase 3 activity is expressed as mean arbitrary units (A.U.) of fluorescence per 30 μg of proteins ± standard error of the mean (SEM) (n = 3). One-way ANOVA was performed between DFX treatment and CONT, FAC or DFX + FAC conditions in non-irradiated (0 Gy) or irradiated (16 Gy) conditions (^*, p-value ≤0.05; ^**, p-value ≤0.01; ^***, p-value ≤0.001). Two-way ANOVA was performed between non-irradiated (0 Gy) condition and irradiated (16 Gy) condition (^$, p-value ≤0.05; ^$$, p-value ≤0.01; ^$$$, p-value ≤0.001). Two-way ANOVA was performed between in DFX treatment in non-irradiated condition (0 Gy) and irradiated (16 Gy) condition (^£, p-value ≤0.05)